Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2016

31.08.2016 | Brief Report

Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype

verfasst von: Thomas Jacob, Joe W. Gray, Megan Troxell, Tania Q. Vu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Activating genetic changes in the phosphatidylinositol-3-kinase (PI3K) signaling pathway are found in over half of invasive breast cancers (IBCs). Previously, we discovered numerous hotspot PIK3CA mutations in proliferative breast lesions. Here, we investigate the spatial nature of PI3K pathway signaling and its relationship with PI3K genotype in breast lesions.

Methods

We identified PI3K phosphosignaling network signatures in columnar cell change (CCL), usual ductal hyperplasia (UDH), ductal carcinoma in situ (DCIS), and IBC in 26 lesions of known PIK3CA genotype from 10 human breast specimens using a hyperspectral-based multiplexed tissue imaging platform (MTIP) to simultaneously quantitate PI3K/MAPK pathway targets (pAKT473, pAKT308, pPRAS40, pS6, and pERK) in FFPE tissue, with single-cell resolution.

Results

We found that breast lesional epithelia contained spatially heterogeneous patterns of PI3K pathway phosphoprotein signatures, even within microscopic areas of CCL, UDH, DCIS, and IBC. Most lesions contained 3–12 unique phosphoprotein signatures within the same microscopic field. The dominant phosphoprotein signature for each lesion was not well correlated with lesion genotype or lesion histology, yet samples from the same patient tended to group together. Further, 5 UDH/CCL lesions across different patients had a common phosphosignature at the epithelial–stromal interface (possible myoepithelial cells) that was distinct from both the adjacent lesional epithelium and distinct from adjacent stroma.

Conclusion

We present the first spatial mapping of PI3K phosphoprotein networks in proliferative breast lesions and demonstrate complex PI3K signaling heterogeneity that defies simple correlation between PIK3CA genotype and phosphosignal pattern.
Literatur
2.
Zurück zum Zitat Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(Suppl 1):12–19CrossRefPubMed Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(Suppl 1):12–19CrossRefPubMed
3.
Zurück zum Zitat Zardavas D, Phillips WA, Loi S (2014) PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 16(1):201CrossRefPubMedPubMedCentral Zardavas D, Phillips WA, Loi S (2014) PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 16(1):201CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Arnedos M et al (2015) Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 12(12):693–704CrossRefPubMed Arnedos M et al (2015) Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 12(12):693–704CrossRefPubMed
5.
Zurück zum Zitat Klarenbeek S, van Miltenburg MH, Jonkers J (2013) Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol 7(2):146–164CrossRefPubMed Klarenbeek S, van Miltenburg MH, Jonkers J (2013) Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol 7(2):146–164CrossRefPubMed
6.
Zurück zum Zitat Gonzalez-Angulo AM, Blumenschein GR Jr (2013) Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313–320CrossRefPubMed Gonzalez-Angulo AM, Blumenschein GR Jr (2013) Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313–320CrossRefPubMed
7.
Zurück zum Zitat Dunlap J et al (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120(2):409–418CrossRefPubMed Dunlap J et al (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120(2):409–418CrossRefPubMed
9.
Zurück zum Zitat Li H et al (2010) PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88(1):150–155CrossRefPubMed Li H et al (2010) PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88(1):150–155CrossRefPubMed
10.
Zurück zum Zitat Kalinsky K et al (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129(2):635–643CrossRefPubMed Kalinsky K et al (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129(2):635–643CrossRefPubMed
11.
Zurück zum Zitat Ang DC et al (2014) Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Mod Pathol 27(5):740–750CrossRefPubMed Ang DC et al (2014) Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Mod Pathol 27(5):740–750CrossRefPubMed
12.
Zurück zum Zitat Newburger DE et al (2013) Genome evolution during progression to breast cancer. Gen Res 23(7):1097–1108CrossRef Newburger DE et al (2013) Genome evolution during progression to breast cancer. Gen Res 23(7):1097–1108CrossRef
13.
Zurück zum Zitat Jahn SW et al (2016) Mutation profiling of usual ductal hyperplasia of the breast reveals activating mutations predominantly at different levels of the PI3K/AKT/mTOR pathway. Am J Pathol 186(1):15–23CrossRefPubMed Jahn SW et al (2016) Mutation profiling of usual ductal hyperplasia of the breast reveals activating mutations predominantly at different levels of the PI3K/AKT/mTOR pathway. Am J Pathol 186(1):15–23CrossRefPubMed
14.
Zurück zum Zitat Isakoff SJ et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed Isakoff SJ et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed
15.
Zurück zum Zitat Dogruluk T et al (2015) Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res 75(24):5341–5354CrossRefPubMed Dogruluk T et al (2015) Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res 75(24):5341–5354CrossRefPubMed
16.
Zurück zum Zitat Stemke-Hale K et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084–6091CrossRefPubMedPubMedCentral Stemke-Hale K et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084–6091CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Korkola JE et al (2015) Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2 + breast cancer. PLoS ONE 10(7):e0133219CrossRefPubMedPubMedCentral Korkola JE et al (2015) Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2 + breast cancer. PLoS ONE 10(7):e0133219CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Roberts E, et al Mapping cancer signaling networks by an integrated multiplexed tissue imaging platform. Technology (in publication) Roberts E, et al Mapping cancer signaling networks by an integrated multiplexed tissue imaging platform. Technology (in publication)
19.
Zurück zum Zitat Hermanson GT (2008) Bioconjugate techniques, 2nd edn. Academic press, New York Hermanson GT (2008) Bioconjugate techniques, 2nd edn. Academic press, New York
20.
21.
Zurück zum Zitat Shah SP et al (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265):809–813CrossRefPubMed Shah SP et al (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265):809–813CrossRefPubMed
22.
Zurück zum Zitat Jensen Dupont et al (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667–677CrossRef Jensen Dupont et al (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667–677CrossRef
23.
Zurück zum Zitat Da Silva L et al (2010) HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 12(4):R46CrossRefPubMedPubMedCentral Da Silva L et al (2010) HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 12(4):R46CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Gonzalez-Angulo AM et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093–1101CrossRefPubMedPubMedCentral Gonzalez-Angulo AM et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093–1101CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Arthur LM et al (2014) Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat 147(1):211–219CrossRefPubMed Arthur LM et al (2014) Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat 147(1):211–219CrossRefPubMed
26.
Zurück zum Zitat Lacroix-Triki M et al (2003) Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 442(6):548–554PubMed Lacroix-Triki M et al (2003) Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 442(6):548–554PubMed
27.
Zurück zum Zitat Lee AH (2013) Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol 66(6):471–477CrossRefPubMed Lee AH (2013) Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol 66(6):471–477CrossRefPubMed
29.
Zurück zum Zitat Janiszewska M et al (2015) In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 47(10):1212–1219CrossRefPubMedPubMedCentral Janiszewska M et al (2015) In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 47(10):1212–1219CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Hammond ME et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72PubMed Hammond ME et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72PubMed
31.
Zurück zum Zitat Polyak K et al (2005) Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 10(3):231–247CrossRefPubMed Polyak K et al (2005) Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 10(3):231–247CrossRefPubMed
32.
Zurück zum Zitat Russell TD et al (2015) Myoepithelial Cell differentiation markers in ductal carcinoma in situ progression. Am J Pathol. 185(11):3076–3089CrossRefPubMed Russell TD et al (2015) Myoepithelial Cell differentiation markers in ductal carcinoma in situ progression. Am J Pathol. 185(11):3076–3089CrossRefPubMed
Metadaten
Titel
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype
verfasst von
Thomas Jacob
Joe W. Gray
Megan Troxell
Tania Q. Vu
Publikationsdatum
31.08.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3962-1

Weitere Artikel der Ausgabe 3/2016

Breast Cancer Research and Treatment 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.